PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 10:07 AM ET

Sponsor Check › Issuer

SP

SELEXYS PHARMACEUTICALS CORP

Corporation · organized in Delaware · formed more than five years before filing · Oklahoma City, OK

$43.2Mreported sold (max)
57investors (max)
3offerings
6Form D filings
2009–2015filing years
0new, last 12 mo
Follow this issuerConnect me with this sponsorEmail me the full reportLook further ↓

Data last updated Oct 23, 2026, 5:45 PM ET · Latest filing by this issuer Feb 23, 2015 · Courts (RECAP) last checked: Oct 24, 2026, 2:11 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

SELEXYS PHARMACEUTICALS CORP is a corporation organized in Delaware (formed more than five years before filing), based in Oklahoma City, OK.

What this means A deal company is usually set up for one investment; its Form D is the notice it files after selling to investors.

It has filed 6 Form D filings (2 originals, 4 amendments) for 3 offerings between Jul 2009 and Feb 2015. The latest filing of each offering reports a combined $51.6M sold of $51.6M offered to 122 investors; industry as reported: biotechnology; latest exemption Rule 506(b).

What this means A repeat filer — 3 separate raises over about 6 years. Amendments are routine updates (an ongoing raise must update its Form D at least once a year).

Key people as listed: David Falconer (executive officer), David Keiser (director), Philip Jones, M.D. (director), Richard Alvarez (executive officer), Rodger McEver, M.D. (director) and 9 more.

What this means These are the people the company itself named as running or promoting it. Tap a name to see every other deal they are on.

Reported money out: $4.86M of proceeds to officers, directors or promoters (latest filing per offering). No sales-compensation recipients are listed.

What this means $4.86M of investor money was reported as going to the people running the deal — about 9.4% of what was sold. The form does not say what for (fees, salaries, buying something from them); ask. No broker was paid — the sponsor sold it directly to investors.

Activity: 0 new offerings in the last 12 months; latest amendment Feb 23, 2015; latest filing Feb 23, 2015.

What this means No new raise filed in the past year — this deal company may be done raising, or simply quiet.

Searched SEC Form ADV bulk data (registered + exempt reporting advisers) (24,962 records as of Oct 2, 2026, 8:00 AM ET) — nothing matched SELEXYS PHARMACEUTICALS CORP.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FINRA, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, WA, WI, WV, WY), property records (NYC, FL, IL and TX counties) — none found.

What this means Nothing turned up where we looked (4 sources). That does not prove there is nothing — it means none was found in those sources on that date.

We compared 6 public filings for SELEXYS PHARMACEUTICALS CORP and found 4 differences: 11% of the money raised went to insiders; Offering amount lowered between filings; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

Business registration (state registry / Secretary of State)

State business registry (Secretary of State) 0 records matched to SELEXYS PHARMACEUTICALS CORP

No Secretary of State record matched in the registries searched (the issuer's reported state of incorporation, DE, has not been searched). Registries searched: AL (Alabama Secretary of State — Business Entity Records (arc-sos.state.al.us), searched by issuer name, data as of Oct 24, 2026); CO (Colorado Secretary of State — Business Entities in Colorado (data.colorado.gov), data as of Oct 23, 2026); CT (Connecticut Secretary of the State — Business Registry (data.ct.gov), data as of Oct 24, 2026); FL (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026); NY (New York Department of State — Corporations and Other Entities (data.ny.gov: All Filings + Active Corporations), data as of Oct 20, 2026); OR (Oregon Secretary of State — Active Businesses, All (data.oregon.gov), data as of Oct 20, 2026); PA (Pennsylvania Department of State — Registered Businesses, Current (data.pa.gov), data as of Oct 6, 2026); TX (Texas Comptroller — Active Franchise Taxpayers incl. Secretary of State file data (data.texas.gov), data as of Oct 24, 2026). Registries of other states have not been searched: many publish no bulk file and require a CAPTCHA or bot challenge on their search page, which we do not bypass (Delaware, for example, offers no public bulk file).

What the community is saying

Community search for SELEXYS PHARMACEUTICALS CORP has not run yet — it is joining a line of 47,429 names; searches run around the clock at the hosts' allowed rate. Searched so far: 641 names.

Community comments are quoted as written by their authors. Sources searched: Bing (site:reddit.com / site:biggerpockets.com) and Reddit's own search, plus DuckDuckGo/Brave/BiggerPockets search when they are answering.

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:11 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: 48 regulators (FINRA, NASAA, 37 states) — crawled Oct 24, 2026, 8:48 AM ET

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched SELEXYS PHARMACEUTICALS CORP..

State securities regulators: Securities regulators searched (64,910 actions): FINRA (38,350 actions, 1995–2026), NASAA (31 actions, 2000–2026; listing starts 1997), AK Division of Banking and Securities (273 actions, 1971–2025), AL Securities Commission (880 actions, 2001–2026), AR Securities Department (1,305 actions, 1998–2026), AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), CO Division of Securities (731 actions, 2001–2026; older years from the Internet Archive (snapshot of 2026-05-02)), CT Department of Banking Securities Division (940 actions, 2006–2026; older years from the Internet Archive (snapshot of 2026-04-22)), DC DISB Securities Bureau (25 actions, 2012–2026), DE DOJ Investor Protection Unit (257 actions, 1987–2026), FL Office of Financial Regulation (49 actions, 2018–2026), GA Secretary of State Securities Division (65 actions, 2015–2026; listing starts 2012), HI DCCA Securities Enforcement Branch (26 actions, 2012–2026), ID Department of Finance Securities Bureau (663 actions, 1994–2026), IL Secretary of State Securities Department (4,122 actions, 2003–2023), KS Insurance Department Securities Division (58 actions), KY Department of Financial Institutions (342 actions, 2005–2026), LA Office of Financial Institutions Securities Division (13 actions, 2010–2025; listing starts 2008), MA Secretary of the Commonwealth Securities Division (125 actions, 2012–2025; live site blocks automated access — loaded from the Internet Archive snapshot of 2026-02-04), MD Attorney General Securities Division (1,054 actions, 2004–2026), ME Office of Securities (539 actions, 2000–2026), MI LARA Corporations, Securities & Commercial Licensing Bureau (201 actions), MO Secretary of State Securities Division (919 actions, 1998–2026), MS Secretary of State Securities Division (209 actions, 1995–2026), MT Commissioner of Securities and Insurance (597 actions, 2000–2026), NC Secretary of State Securities Division (265 actions, 2004–2024), ND Securities Department (711 actions, 1990–2026; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2026-01-06), NH Bureau of Securities Regulation (402 actions, 2002–2026), NM Regulation and Licensing Department Securities Division (90 actions, 2010–2025), NV Secretary of State Securities Division (118 actions, 2018–2026), NY Attorney General Investor Protection Bureau (44 actions, 2012–2026), OH Division of Securities (327 actions, 1993–2006), OK Department of Securities (2,531 actions, 1998–2026), OR Division of Financial Regulation (589 actions, 1988–2026), PA Department of Banking and Securities (1,448 actions, 2008–2024; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2024-08-09), RI DBR Securities Division (98 actions, 2005–2025), SC Attorney General Securities Division (540 actions, 2006–2026), SD Division of Insurance – Securities Regulation (106 actions, 2017–2026), TN Department of Commerce and Insurance Securities Division (405 actions, 1992–2026), TX State Securities Board (936 actions, 1999–2026), UT Division of Securities (772 actions, 2000–2026; older years from the Internet Archive (snapshot of 2010-05-27)), VT DFR Securities Division (137 actions, 2010–2026), WA DFI (2,039 actions, 2001–2026), WI DFI Division of Securities (1,072 actions, 1998–2026), WV Securities Commission (State Auditor) (64 actions), WY Secretary of State Compliance Division (6 actions, 2016–2024) — last crawled Oct 24, 2026, 8:48 AM ET. No machine-readable public listing today for IA, IN, MN, NE, NJ, VA (see docs/state-regulators.md).

3. Bankruptcies

None found in sources searched — federal bankruptcy courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:11 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

No comparisons published

What is compared

No public statement by this issuer has been collected yet, so there is nothing to compare. Sources compared: the sponsor's own website (known from the issuer's own filings — Form C issuer website, EDGAR company profile — an approved profile claim or Form ADV Item 1.I of its matched adviser) · SEC Form D · SEC Form ADV (IAPD) · Internet Archive · No website is on file for this issuer yet.

4 differences found between the filings for SELEXYS PHARMACEUTICALS CORP (compared 6 filings on Oct 24, 2026)

Note · Feb 23, 2015

11% of the money raised went to insiders — SELEXYS PHARMACEUTICALS CORP

The Feb 23, 2015 Form D/A reports $43,196,831 sold and $4,864,000 of the proceeds used for payments to officers, directors or promoters (marked as an estimate). Issuer's note: "Estimated amount includes officers' salaries and bonuses paid since the initial filing and estimated salaries and potential bonuses for the period over which the proceeds of the offering are expected ".

What this means The filing reports how much of the money raised was paid to insiders. Over 10% is high for most deals. Ask what it paid for.

Form D/A · Feb 23, 2015 ↗SELEXYS PHARMACEUTICALS CORP — PartnerFacts page ↗
Sources
Note · Oct 2, 2012 – Feb 23, 2015

Offering amount lowered between filings — SELEXYS PHARMACEUTICALS CORP

The Oct 2, 2012 filing says $45,659,537 offered; the Feb 23, 2015 Form D/A says $43,196,831.

What this means The target raise got smaller. That can mean the plan shrank or the sponsor stopped early. Ask what changed in the deal.

Form D (earlier) · Oct 2, 2012 ↗Form D/A (later) · Feb 23, 2015 ↗SELEXYS PHARMACEUTICALS CORP — PartnerFacts page ↗
Sources
Note · Dec 1, 2010 – Apr 20, 2011

Minimum investment changed between filings — SELEXYS PHARMACEUTICALS CORP

The Dec 1, 2010 filing lists a minimum of $100,000; the Apr 20, 2011 Form D/A lists $25,000.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D (earlier) · Dec 1, 2010 ↗Form D/A (later) · Apr 20, 2011 ↗SELEXYS PHARMACEUTICALS CORP — PartnerFacts page ↗
Sources
Note · Nov 4, 2011 – Oct 2, 2012

Address moved from Edmond, OK to Oklahoma City, OK — SELEXYS PHARMACEUTICALS CORP

The people listed on the Nov 4, 2011 filing give Edmond, OK; on the Oct 2, 2012 filing they give Oklahoma City, OK.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D/A · Nov 4, 2011 ↗Form D · Oct 2, 2012 ↗SELEXYS PHARMACEUTICALS CORP — PartnerFacts page ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

0 of 3 offerings report sales commissions; 0 report finder's fees; 1 reports proceeds to related persons totalling $4,864,000. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Feb 23, 2015 D/A
File 021-184899
$0$0$4,864,000 (est.)
Estimated amount includes officers' salaries and bonuses paid since the initial filing and estimated salaries and potential bonuses for the period over which the proceeds of the offering are expected to be expended.
None listed on this filingEDGAR ↗
Nov 4, 2011 D/A
File 021-151235
$0$0$0None listed on this filingEDGAR ↗
Jul 2, 2009 D/A
File 021-121452
$0$0$0 (est.)None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Property records 0 documents · 0 ownership records · last checked Oct 24, 2026, 9:34 AM ET · NYC and Cook County lookup still to run

0 recorded documents and 0 ownership records matched to SELEXYS PHARMACEUTICALS CORP in the sources searched.

Not found in sources searched as of Oct 24, 2026, 9:34 AM ET: Hillsborough County FL Clerk of Court Official Records daily index (publicrec.hillsclerk.com D/P/M files), 2 daily files (Oct 14, 2026 to Oct 15, 2026) — loaded Oct 23, 2026, 8:59 PM ET; Harris County TX (HCAD ownership rolls 2005–2026) — 1,032,426 records, loaded Oct 24, 2026, 8:00 AM ET; Dallas County TX (DCAD ownership rolls 2021–2027) — 285,535 records, loaded Oct 24, 2026, 8:20 AM ET; Hillsborough County FL (FL DOR 2026 ownership roll + Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026), Miami-Dade County FL (FL DOR 2026 ownership roll), Broward County FL (FL DOR 2026 ownership roll), Palm Beach County FL (FL DOR 2026 ownership roll) — 514,336 records, loaded Oct 24, 2026, 8:25 AM ET; King County WA (Assessor sale records 0000-00-00–2026-10-14; no owner-of-record names published) — 538,619 records, loaded Oct 24, 2026, 8:27 AM ET; Cook County IL (Assessor sale records 1982–2026 + ownership rolls 2014–2026) — 1,031,843 records, loaded Oct 24, 2026, 9:05 AM ET. Still to be looked up for this issuer: NYC ACRIS via NYC Open Data (Real Property Parties 636b-3b5g, Master bnx9-e6tj, Legals 8h5j-fqxa, Document Control Codes 7isb-wh4c) · NYC PLUTO ownership via NYC Open Data (64uk-42ks) · Cook County IL Assessor via Cook County Open Data (Parcel Sales wvhk-k5uv; Parcel Addresses 3723-97qp). Records in other counties, and recorder indexes we do not yet cover, were not searched.

Property records coverage: New York City (ACRIS recorded documents and PLUTO ownership, looked up per issuer when its page is viewed; re-checked when the page is viewed again more than 30 days after the last check); Harris County TX (ownership only, no deed, mortgage or sale records; HCAD ownership rolls 2005–2026); Dallas County TX (ownership only, no deed, mortgage or sale records; DCAD ownership rolls 2021–2027); Hillsborough County FL (FL DOR 2026 ownership roll + Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026), Miami-Dade County FL (FL DOR 2026 ownership roll), Broward County FL (FL DOR 2026 ownership roll), Palm Beach County FL (FL DOR 2026 ownership roll); King County WA (Assessor sale records 0000-00-00–2026-10-14; no owner-of-record names published); Cook County IL (Assessor sale records 1982–2026 + ownership rolls 2014–2026); also looked up per issuer when its page is viewed. Recorder indexes (party names on deeds, mortgages and liens) in TX, AZ, NV, CA and WA counties and outside the Clerk index in FL, mortgages and liens outside NYC and Hillsborough County, lis pendens and foreclosure notices everywhere, Los Angeles County CA, Clark County NV, New York City bulk pass (not finished; per-issuer lookups only so far), Maricopa County AZ (loader ready; commercial-purpose statement not yet filed), Salt Lake County UT, and all other counties are not covered — not searched. Last refresh by source: Cook County IL Assessor via Cook County Open Data (Parcel Sales wvhk-k5uv; Parcel Addresses 3723-97qp) Oct 24, 2026, 9:05 AM ET; Cook County IL Assessor via Cook County Open Data (Parcel Sales wvhk-k5uv; Parcel Addresses 3723-97qp) Oct 24, 2026, 8:30 AM ET; King County WA Assessor Real Property Sales extract (EXTR_RPSale.csv) Oct 24, 2026, 8:27 AM ET; Florida DOR NAL roll (Palm Beach 60) Oct 24, 2026, 8:25 AM ET; Florida DOR NAL roll (Broward 16) Oct 24, 2026, 8:24 AM ET; Florida DOR NAL roll (Dade 23) Oct 24, 2026, 8:23 AM ET; Florida DOR NAL roll (Hillsborough 39) Oct 24, 2026, 8:21 AM ET; Dallas Central Appraisal District ACCOUNT_INFO.CSV Oct 24, 2026, 8:20 AM ET; Harris County Appraisal District real_acct.txt Oct 24, 2026, 8:00 AM ET; Hillsborough County FL Clerk daily index Oct 23, 2026, 8:59 PM ET. NYC and Cook County are also looked up per issuer when its page is viewed; the most recent such lookup on this site finished Oct 24, 2026, 3:30 AM ET. Parties are named as the recorder's index names them (role suffixes as recorded); no address, account number or trust date is shown for an individual, and individual owners of record (home ownership) are not matched or shown. Items still in human review are not shown.

Offerings (SEC Form D)

Each filing as reported by the issuer, newest first. Open a row for the full plain-English detail. D = original notice, D/A = amendment.

Offerings at a glance — 3 offerings, 6 filings (one row per SEC file number)
File no.Original Form DLatest filingAmendmentsOffered (latest)Sold (latest)Industry (latest)
021-184899Oct 2, 2012 EDGAR ↗Feb 23, 2015 D/A EDGAR ↗1
latest Feb 23, 2015
$43,196,831$43,196,831Biotechnology
021-151235Dec 1, 2010 EDGAR ↗Nov 4, 2011 D/A EDGAR ↗2
latest Nov 4, 2011
$5,000,000$5,000,000Biotechnology
021-121452not in our indexJul 2, 2009 D/A EDGAR ↗1
latest Jul 2, 2009
$3,435,000$3,435,000Biotechnology

Offerings are grouped by SEC file number; rows without a file number (not yet retrieved from EDGAR) are shown as their own offering until the link is fetched.

Feb 23, 2015 D/A Biotechnology — $43,196,831 sold of $43,196,831 · 57 investors EDGAR ↗
FilingForm D/A (amendment) filed Feb 23, 2015 · amends 0001140361-12-042306 ↗
SEC file no. 021-184899 · accession 0001140361-15-008408 · filing 2 of 2 in this offering
Raise progress$43,196,831 sold of $43,196,831 offered (100%) · $0 remaining · first sale Sep 17, 2012
Issuer's note: Includes warrant issued for $10,000,000, $24,459,532 of Series A Preferred Shares at the initial closing ($10,659,534 of which was from the conversion of outstanding notes), and $8,737,299 of Series A Preferred Shares at the second closing.
Filing timingDate of first sale: Sep 17, 2012 · Original Form D filed: Oct 2, 2012 (15 days after first sale) · This amendment (Form D/A) filed: Feb 23, 2015
This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn.
Time since first sale5,151 days (14.1 years)
Annual amendmentsIssuer reported the offering may last more than one year. This filing is an amendment dated Feb 23, 2015. Most recent amendment for this offering in our index: this filing, Feb 23, 2015.
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors57 total · issuer reported no non-accredited investors
Exemption claimedRule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted$13,217
Securities offeredEquity; Option, warrant or other right to acquire
Entity detailsOrganized in DELAWARE · formed more than five years before filing · revenue range: No Revenues (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $4,864,000 (est.)
Issuer's note: Estimated amount includes officers' salaries and bonuses paid since the initial filing and estimated salaries and potential bonuses for the period over which the proceeds of the offering are expected to be expended.
Signed byDouglas A. Branch, Secretary (Feb 23, 2015)
Changes vs previous filing
  • total sold: $34,459,532 (Oct 2, 2012) → $43,196,831 (Feb 23, 2015)
  • total offering: $45,659,537 (Oct 2, 2012) → $43,196,831 (Feb 23, 2015)
  • remaining: $11,200,005 (Oct 2, 2012) → $0 (Feb 23, 2015)
  • proceeds to insiders: $0 (Oct 2, 2012) → $4,864,000 (Feb 23, 2015)
  • exemption: Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) (Oct 2, 2012) → Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed (Feb 23, 2015)
Compared with the D filed Oct 2, 2012 (EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn.
Market contextMinimum investment: $13,217. Typical range for similar offerings: $10,000–$50,000.
Offering size: $43,196,831. Typical range: $2,000,000–$19,999,994.
Investors: 57. Typical range: 2–16.
"Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Oct 2, 2012 D Biotechnology — $34,459,532 sold of $45,659,537 · 57 investors EDGAR ↗
FilingForm D filed Oct 2, 2012
SEC file no. 021-184899 · accession 0001140361-12-042306 · filing 1 of 2 in this offering
Raise progress$34,459,532 sold of $45,659,537 offered (75%) · $11,200,005 remaining · first sale Sep 17, 2012
Issuer's note: Includes warrant issued for $10,000,000, and 4,951,903 shares of Series A Preferred sold for $24,459,532, $10,659,534 of which is from the conversion of outstanding notes. $10,000,000 remains subject to milestones under Series A Stock Purchase Agreement.
Filing timingDate of first sale: Sep 17, 2012 · Form D filed: Oct 2, 2012 (15 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale5,151 days (14.1 years)
Annual amendmentsIssuer reported the offering may last more than one year. Most recent amendment for this offering in our index: Feb 23, 2015 (EDGAR ↗).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors57 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$13,217
Securities offeredEquity; Option, warrant or other right to acquire
Entity detailsOrganized in DELAWARE · formed more than five years before filing · revenue range: No Revenues (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 (est.)
Signed byDouglas A. Branch, Secretary (Oct 2, 2012)
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Nov 4, 2011 D/A Biotechnology — $5,000,000 sold of $5,000,000 · 34 investors EDGAR ↗
FilingForm D/A (amendment) filed Nov 4, 2011 · amends 0001140361-10-047606 ↗
SEC file no. 021-151235 · accession 0001140361-11-051706 · filing 3 of 3 in this offering
Raise progress$5,000,000 sold of $5,000,000 offered (100%) · $0 remaining · first sale Nov 21, 2010
Issuer's note: Includes a $1,000,000 Overallotment Option which was exercised by Selexys. Selexys raised $2,800,000 in the first tranche and $2,200,000 in the reopen.
Filing timingDate of first sale: Nov 21, 2010 · Original Form D filed: Dec 1, 2010 (10 days after first sale) · This amendment (Form D/A) filed: Nov 4, 2011
This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn.
Time since first sale5,817 days (15.9 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. This filing is an amendment dated Nov 4, 2011. Most recent amendment for this offering in our index: this filing, Nov 4, 2011.
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors34 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$25,000
Securities offeredDebt; Other: debt convertible into equity
Entity detailsOrganized in DELAWARE · formed more than five years before filing · revenue range: No Revenues (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed byDouglas A. Branch, Secretary (Nov 2, 2011)
Changes vs previous filing
  • total sold: $2,800,000 (Apr 20, 2011) → $5,000,000 (Nov 4, 2011)
  • remaining: $2,200,000 (Apr 20, 2011) → $0 (Nov 4, 2011)
  • investors: 25 (Apr 20, 2011) → 34 (Nov 4, 2011)
Compared with the D/A filed Apr 20, 2011 (EDGAR ↗). The issuer's form cites 0001140361-10-047606 as the filing it amends; the comparison here is with the filing immediately before this one in the same offering. Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn.
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Apr 20, 2011 D/A Biotechnology — $2,800,000 sold of $5,000,000 · 25 investors EDGAR ↗
FilingForm D/A (amendment) filed Apr 20, 2011 · amends 0001140361-10-047606 ↗
SEC file no. 021-151235 · accession 0001140361-11-022664 · filing 2 of 3 in this offering
Raise progress$2,800,000 sold of $5,000,000 offered (56%) · $2,200,000 remaining · first sale Nov 21, 2010
Issuer's note: Includes a $1,000,000 Overallotment Option exercisable in the sole discretion of Selexys. Although the offering period has ended, Selexys has retained the right to reopen the offering for up to 90 days in certain circumstances.
Filing timingDate of first sale: Nov 21, 2010 · Original Form D filed: Dec 1, 2010 (10 days after first sale) · This amendment (Form D/A) filed: Apr 20, 2011
This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn.
Time since first sale5,817 days (15.9 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. This filing is an amendment dated Apr 20, 2011. Most recent amendment for this offering in our index: Nov 4, 2011 (EDGAR ↗).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors25 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$25,000
Securities offeredDebt; Other: debt convertible into equity
Entity detailsOrganized in DELAWARE · formed more than five years before filing · revenue range: No Revenues (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 (est.)
Signed byDouglas A. Branch, Secretary (Apr 12, 2011)
Changes vs previous filing
  • total sold: $200,000 (Dec 1, 2010) → $2,800,000 (Apr 20, 2011)
  • remaining: $4,800,000 (Dec 1, 2010) → $2,200,000 (Apr 20, 2011)
  • investors: 2 (Dec 1, 2010) → 25 (Apr 20, 2011)
  • minimum investment: $100,000 (Dec 1, 2010) → $25,000 (Apr 20, 2011)
  • securities offered: Other: debt convertible into equity (Dec 1, 2010) → Debt; Other: debt convertible into equity (Apr 20, 2011)
Compared with the D filed Dec 1, 2010 (EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn.
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Dec 1, 2010 D Biotechnology — $200,000 sold of $5,000,000 · 2 investors EDGAR ↗
FilingForm D filed Dec 1, 2010
SEC file no. 021-151235 · accession 0001140361-10-047606 · filing 1 of 3 in this offering
Raise progress$200,000 sold of $5,000,000 offered (4%) · $4,800,000 remaining · first sale Nov 21, 2010
Issuer's note: Includes a $1,000,000 Overallotment Option exercisable in the sole discretion of Selexys.
Filing timingDate of first sale: Nov 21, 2010 · Form D filed: Dec 1, 2010 (10 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale5,817 days (15.9 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Nov 4, 2011 (EDGAR ↗).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors2 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$100,000
Securities offeredOther: debt convertible into equity
Entity detailsOrganized in DELAWARE · formed more than five years before filing · revenue range: No Revenues (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 (est.)
Signed byDouglas A. Branch, Secretary (Dec 1, 2010)
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Jul 2, 2009 D/A Biotechnology — $3,435,000 sold of $3,435,000 · 31 investors EDGAR ↗
FilingForm D/A (amendment) filed Jul 2, 2009 · amends a pre-2008 paper filing (EDGAR accession 9999999997-08-035835, no electronic copy)
SEC file no. 021-121452 · accession 0001442824-09-000002
Raise progress$3,435,000 sold of $3,435,000 offered (100%) · $0 remaining · first sale Aug 11, 2008
Issuer's note: The Company offered a maximum of $3,500,000 in convertible promissory notes pursuant to a PPM dated July 15, 2008, of which $3,435,000 was sold.
Filing timingDate of first sale: Aug 11, 2008 · Original Form D filed: not in our index (filed before 2008, under another file number, or its link has not yet been retrieved from EDGAR) · This amendment (Form D/A) filed: Jul 2, 2009
This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn.
Time since first sale6,649 days (18.2 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. This filing is an amendment dated Jul 2, 2009. Most recent amendment for this offering in our index: this filing, Jul 2, 2009.
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors31 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$10,000
Securities offeredDebt; Other: debt convertible into equity
Entity detailsOrganized in DELAWARE · formed more than five years before filing · revenue range: No Revenues (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryBiotechnology
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 (est.)
Signed byScott Rollins, President and Chief Executive Officer (Jun 18, 2009)
Changes vs previous filingPrevious filing in this offering: a pre-2008 paper filing that is not on EDGAR in electronic form. No comparison is shown.
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Amendment history — 4 amendments on this page, each compared with the filing before it in the same offering
Amendment filedFile no.Compared withWhat changed (both values as filed)
Feb 23, 2015 EDGAR ↗021-184899Oct 2, 2012 Dtotal sold: $34,459,532 (Oct 2, 2012) → $43,196,831 (Feb 23, 2015) · total offering: $45,659,537 (Oct 2, 2012) → $43,196,831 (Feb 23, 2015) · remaining: $11,200,005 (Oct 2, 2012) → $0 (Feb 23, 2015) · and 2 more (open the filing above)
Nov 4, 2011 EDGAR ↗021-151235Apr 20, 2011 D/Atotal sold: $2,800,000 (Apr 20, 2011) → $5,000,000 (Nov 4, 2011) · remaining: $2,200,000 (Apr 20, 2011) → $0 (Nov 4, 2011) · investors: 25 (Apr 20, 2011) → 34 (Nov 4, 2011)
Apr 20, 2011 EDGAR ↗021-151235Dec 1, 2010 Dtotal sold: $200,000 (Dec 1, 2010) → $2,800,000 (Apr 20, 2011) · remaining: $4,800,000 (Dec 1, 2010) → $2,200,000 (Apr 20, 2011) · investors: 2 (Dec 1, 2010) → 25 (Apr 20, 2011) · and 2 more (open the filing above)
Jul 2, 2009 EDGAR ↗021-121452not in our indexNo comparison (previous filing not in our index)

Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Values as filed; no conclusion is drawn.

All Form D filings for this CIK on SEC EDGAR ↗. History: 0 new offerings in the last 12 months (new offering = a Form D that is not an amendment) · most recent filing Feb 23, 2015. Industry as reported, by offering: All 3 offerings reported: Biotechnology (2009–2012).

Key people 14

Officers, directors and promoters the issuer itself named on its Form D. Tap a name for every other deal they are on.

NameRelationshipAddress stateOn filings (first → last)Also listed on
DF David FalconerExecutive OfficerOKJul 2, 2009 → Feb 23, 2015
on 6 of 6 filings
listed on the latest filing
—
DK David KeiserDirectorCTOct 2, 2012 → Feb 23, 2015
on 2 of 6 filings
listed on the latest filing
1 other issuer
PD Philip Jones, M.D.DirectorOKDec 1, 2010 → Feb 23, 2015
on 5 of 6 filings
listed on the latest filing
1 other issuer
RA Richard AlvarezExecutive OfficerOKJul 2, 2009 → Feb 23, 2015
on 6 of 6 filings
listed on the latest filing
2 other issuers
RD Rodger McEver, M.D.DirectorOKDec 1, 2010 → Feb 23, 2015
on 5 of 6 filings
listed on the latest filing
1 other issuer
RR Russell RotherExecutive OfficerOKOct 2, 2012 → Feb 23, 2015
on 2 of 6 filings
listed on the latest filing
2 other issuers
SD Scott Rollins, Ph.D.Executive Officer, DirectorOKDec 1, 2010 → Feb 23, 2015
on 5 of 6 filings
listed on the latest filing
1 other issuer
TF Todd FoleyDirectorMAOct 2, 2012 → Feb 23, 2015
on 2 of 6 filings
listed on the latest filing
18 other issuers
TW Tom WalkerDirectorOKJul 2, 2009 → Nov 4, 2011
on 4 of 6 filings
not listed on the latest filing (Feb 23, 2015)
—
WD William Paiva, Ph.D.DirectorOKDec 1, 2010 → Nov 4, 2011
on 3 of 6 filings
not listed on the latest filing (Feb 23, 2015)
—
PJ Philip JonesDirectorOKJul 2, 2009
on 1 of 6 filings
not listed on the latest filing (Feb 23, 2015)
1 other issuer
RM Rodger McEverDirectorOKJul 2, 2009
on 1 of 6 filings
not listed on the latest filing (Feb 23, 2015)
—
SR Scott Rollins
person page: Scott A. Rollins
Executive Officer, DirectorOKJul 2, 2009
on 1 of 6 filings
not listed on the latest filing (Feb 23, 2015)
1 other issuer
WP William PaivaDirectorOKJul 2, 2009
on 1 of 6 filings
not listed on the latest filing (Feb 23, 2015)
5 other issuers

Executive officers, directors and promoters as self-reported by the issuer, one row per person. Spellings of the same name (same first and last name, or the same full name that EDGAR split differently into middle and last name) with no conflicting middle initial are shown on one row (none on this issuer); dates and counts come from the filings that list each name. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗.

Connections

Other issuers listing the same people:

Shared address: this business address appears on filings for 6 other issuers. Stated as a count only (suite numbers ignored) — many addresses are shared office buildings or registered agents. As of Oct 23, 2026, 5:45 PM ET.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Adviser registration (Form ADV)

Searched SEC Form ADV bulk data (registered + exempt reporting advisers) (24,962 records as of Oct 2, 2026, 8:00 AM ET) — nothing matched SELEXYS PHARMACEUTICALS CORP.

Meta advertising

No Meta Pixel ids or Facebook / Instagram page links on file for SELEXYS PHARMACEUTICALS CORP as of Oct 24, 2026 — the sponsor website is read for them once it is on file (runs automatically). Meta Ad Library: not searched by PartnerFacts (no API access); a one-tap Ad Library search is under Look further.

Public profiles

Public profiles official links and public statements, each with its source and date

No website or social profile named in SELEXYS PHARMACEUTICALS CORP's SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #306,230 of 374,652 in line (1,386 issuers searched so far).

Sources searched for a website: Form C data set (issuer websites as filed), Form ADV data set (Item 1.I of matched advisers) — as of Oct 23, 2026, 11:20 PM ET: none on file for this issuer. The sponsor website, the Internet Archive and GDELT news index are read only once a site is on file; a sponsor's website comes from the issuer's own filings (Form C issuer website; EDGAR company profile), an approved profile claim, Form ADV Item 1.I of its matched adviser, or a web search for the issuer name confirmed on the site's own homepage. We never collect personal or family accounts.

Entity standing: not checked (no official programmatic source for OK yet).

Export this report as PDF (all source links + data timestamp) · Premium

Request diligence pack (Premium) PartnerFacts asks the sponsor for the standard information pack and delivers it to you labelled "provided by the sponsor".

Corrections log

No corrections have been requested for this page.

Filing-to-filing changes are in Amendment history above.

Facts from public records only, each linked to its source. No ratings, no opinions. Request a correction · Claim this profile · Facts policy

Email me the full report

The complete public-record profile for SELEXYS PHARMACEUTICALS CORP, plus the weekly new-filings list.

What do you want to do?

Only "Connect me" shares your details — with this sponsor, at a flat price we charge them, never tied to whether you invest. "Just researching" shares nothing.

Request a correction

Free. Tell us what's wrong and, if you can, where the correct public record is. Every request is logged with its status (received → under review → fixed / confirmed with source).

Sponsor response

Sponsors may add a sourced explanation next to any fact on this page. Reviewed before publishing; never edits the public record.

Claim this profile (sponsors)

Free. Get the "Claimed by sponsor" chip and a confirmed contact for corrections. Claiming never changes the public-record section.

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Oklahoma City, OK). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn companies ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗Oklahoma state courts — find the court ↗Delaware CourtConnect ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

Oklahoma Secretary of State business search ↗Delaware Secretary of State business search ↗OpenCorporates ↗